선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
Bull: VYVGART achieves standard-of-care status in 5+ indications simultaneously, driving margins toward 40%+.
FcRn Class Competition: Next-generation competitors outcompete on pricing or efficacy, eroding market share.
argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities.
argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities.
IP-protected antibody platform
Pipeline-in-a-product strategy
High demand for specialized autoimmune therapeutic platforms.
Strong Buy based on durable hyper-growth and multiple secondary indications.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
In a sustained high-cost environment where CIDP expansion falters, valuation relies entirely on established gMG revenues.
Next-generation competitors erode pricing power, and secondary indications face regulatory delays.
Next-generation competitors outcompete on pricing or efficacy, eroding market share.
Regulatory delays or clinical failures across 3+ secondary indications cap revenue.
투자 논리를 약화시킬 수 있는 다섯 가지 변화입니다.
Failing to sustain operating profitability targets signals unconstrained commercialization expenses and clinical trial overhead, eroding operating leverage and undermining the core profitability profile required to justify current valuation multiples.
현재:25.4% for the period ended 2025-12-31
다음이면 경고< 15.0% for any fiscal year through FY2027
IP-protected antibody platform
Pipeline-in-a-product strategy
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Unavailable
The highlighted base cell is anchored to valuation synthesis sensitivity reference ($1,486.48). It is the reference value for this grid, not a separate standalone fair-value claim.
FCFF DCF remains positive at the base case: base FCFF $876.0M after capex $103.8M, with terminal value at 70.6% of enterprise value. No FCF cliff is projected unless capex/revenue or gross margin materially resets.
VYVGART achieves standard-of-care status in 5+ indications simultaneously, driving margins toward 40%+.
Solid execution in gMG and CIDP with steady margin expansion towards the 30% target.
If margins hit 30% and revenue grows 22%+, valuation trends toward bull case.
If margins hit 30% and revenue grows 22%+, valuation trends toward bull case.
If margins hit 30% and revenue grows 22%+, valuation trends toward bull case.
If margins hit 30% and revenue grows 22%+, valuation trends toward bull case.
Warning level: < 15.0% for any fiscal year through FY2027. Failing to sustain operating profitability targets signals unconstrained commercialization expenses and clinical trial overhead, eroding operating leverage and undermining the core profitability profile required to justify current valuation multiples.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| 매출 | 4,153,482,000 |
|---|---|
| 매출원가 | 450,665,000 |
| 매출총이익 | 3,702,817,000 |
| 영업비용 | 2,648,202,000 |
| 영업이익 | 1,054,615,000 |
| 영업외 항목 및 세금 | 237,420,000 |
| 순이익 | 1,292,035,000 |
| 총자산 | 8,682,698,000 |
|---|---|
| 현금 | 3,491,289,000 |
| 유동자산 | 6,899,104,000 |
| 총부채 | 1,359,606,000 |
| 유동부채 | 1,320,186,000 |
| 주주자본 | 7,323,092,000 |
2026-05-20 분석에 사용된 시점 재무 데이터입니다.
| 기간 | 매출 | EBITDA | 순이익 | 영업 현금흐름 | 잉여 현금흐름 | 자본적 지출 | 감가상각비 | 주식 기반 보상 | 자사주 매입 | 지급 배당금 | 순부채 발행 | 투자 현금흐름 | 재무 현금흐름 | 기초 현금 | 기말 현금 | 현금 및 투자자산 | 총부채 | 영업이익률 | ROIC | WACC | ROIC−WACC 스프레드 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 4.1억 | -6.2억 | -7.1억 | -8.6억 | -9.7억 | 1억 | 1억 | 1.6억 | — | — | -416.5만 | — | — | — | — | 8억 | 1242.6만 | -176.2% | — | — | — |
| 2023-12-31 | 12.3억 | -1.9억 | -3억 | -4.2억 | -4.6억 | 4381.2만 | 1.1억 | 2.3억 | — | — | -380.1만 | — | — | — | — | 20.5억 | 2000만 | -34.3% | — | — | — |
| 2024-12-31 | 21.9억 | 1.1억 | 8.3억 | -8274.7만 | -1.5억 | 6830.1만 | 1752.7만 | 2.4억 | — | — | -763.8만 | — | — | — | — | 15억 | 3905.3만 | -0.8% | — | — | — |
| 2025-12-31 | 41.5억 | 13.1억 | 12.9억 | 6.9억 | 5.7억 | 1.1억 | 2810.2만 | 2.5억 | — | — | -410.7만 | — | — | — | — | 34.9억 | 4716만 | 25.4% | — | — | — |
ARGX trades at 21.8x forward earnings against a peer median of 15.9x; EV/EBITDA of 34.2x against a peer median of 17.2x; 6 peers.
Transformation build phase.
High demand for specialized autoimmune therapeutic platforms.
Increased regulatory scrutiny and pricing pressure.
Transformation build phase.
Maintain full weight; volatility expected around readouts.
Reevaluate if structural thesis breaks or price exceeds $2700.
Strong Buy. Pipeline diversity reduces binary outcome risk.
High conviction in long-term pipeline-in-a-product strategy.
Strong Buy. Pipeline diversity reduces binary outcome risk.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Failure to cross 15% operating margins by FY2027 due to sustained high SG&A.
Rejection of expanded therapeutic indications leaves the franchise overly dependent on existing neuromuscular revenues, drastically lowering long-term addressable market scale and restricting peak commercial sales potential.
현재:No secondary indication rejections filed as of 2026-05-20
다음이면 경고>= 1 formal regulatory rejection or Complete Response Letter from the FDA or EMA across secondary indications within any 12-month period
Multiple late-stage clinical trial failures would invalidate the broad pipeline-in-a-product expansion narrative, stranding significant research capital and capping total addressable market expansion.
현재:Zero major pipeline trial failures as of 2026-05-20
다음이면 경고> 3 clinical trial primary endpoint failures across secondary indications within any 24-month period
Sharp revenue growth deceleration indicates aggressive competitor entry in the core FcRn class and pricing pressure, eroding commercial dominance and compressing top-line expansion trajectory.
현재:89.6% for the period ended 2025-12-31
다음이면 경고< 25.0% over any trailing twelve-month period
Significant compression in gross profitability signals intense pricing competition, mandatory rebates, or escalating manufacturing unit costs, reducing the gross cash flows needed to support commercial infrastructure.
현재:89.1% for the period ended 2025-12-31
다음이면 경고< 80.0% over any trailing twelve-month period
Under the moderate discount rate, US$236 comes from forecast-period earnings and US$394 from the long-term value, totaling US$630.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Warning level: >= 1 formal regulatory rejection or Complete Response Letter from the FDA or EMA across secondary indications within any 12-month period. Rejection of expanded therapeutic indications leaves the franchise overly dependent on existing neuromuscular revenues, drastically lowering long-term addressable market scale and restricting peak commercial sales potential.
Warning level: > 3 clinical trial primary endpoint failures across secondary indications within any 24-month period. Multiple late-stage clinical trial failures would invalidate the broad pipeline-in-a-product expansion narrative, stranding significant research capital and capping total addressable market expansion.
Warning level: < 25.0% over any trailing twelve-month period. Sharp revenue growth deceleration indicates aggressive competitor entry in the core FcRn class and pricing pressure, eroding commercial dominance and compressing top-line expansion trajectory.
Warning level: < 80.0% over any trailing twelve-month period. Significant compression in gross profitability signals intense pricing competition, mandatory rebates, or escalating manufacturing unit costs, reducing the gross cash flows needed to support commercial infrastructure.
| 마진 |
|---|
| ARGX | argenx SE | $49.9B | 21.8x | 10.5x | 34.2x | — | — |
| VRTX | Vertex Pharmaceuticals Incorporated | 20.1x | 9.0x | 21.1x | 24.2% | 38.1% | |
| REGN | Regeneron Pharmaceuticals Inc. | 11.7x | 4.4x | 13.3x | 14.5% | 20.7% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 21.0x | 9.1x | 48.3x | 90.4% | 23.0% | |
| INCY | Incyte Corporation | 10.6x | 3.6x | 9.8x | 30.8% | 25.6% | |
| MRNA | Moderna Inc. | -11.0x | 8.2x | -6.2x | -36.6% | -131.1% |
